1. Home
  2. XBIO vs NCNA Comparison

XBIO vs NCNA Comparison

Compare XBIO & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$3.69

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$1.50

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIO
NCNA
Founded
N/A
1997
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
5.7M
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
XBIO
NCNA
Price
$3.69
$1.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.9K
30.0K
Earning Date
05-13-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
38.52
N/A
EPS
N/A
N/A
Revenue
$2,976,411.00
N/A
Revenue This Year
$2.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.04
N/A
52 Week Low
$1.90
$1.21
52 Week High
$13.93
$7.01

Technical Indicators

Market Signals
Indicator
XBIO
NCNA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
XBIO
NCNA

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.

Share on Social Networks: